Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rebooting Sensitivity to Checkpoint Blockade Therapy in Triple-Negative Breast Cancer With Isunakinra (RESETT- I)

NCT07698106 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT07698106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07698106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rebooting Sensitivity to Checkpoint Blockade Therapy in Triple-Negative Breast Cancer With Isunakinra (RESETT- I)
Lead sponsor
University Health Network, Toronto
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
August 31, 2034
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer (tnbc)